Iam BCR-ABL Kit
Iam BCR-ABL Kit
Background
The BCR-ABL fusion gene codes for an oncogenic protein with elevated tyrosine kinase activity, which is responsible for the neoplastic transformation. The timely and accurate molecular detection of the BCR-ABL transcripts is mandatory in order to diagnose Philadelphia Positive Leukemias allowing implementation of targeted therapies, which are able to selectively inactivate the BCR-ABL chimeric protein.
Why to choose it
A simplified, comprehensive and rapid solution for the reliable molecular identification of BCR-ABL translocations.
Benefits
Enhanced formulation
Comprehensive detection of common and rare BCR-ABL isoforms
Clinical studies performed on the limited number of available samples (n=14) have demonstrated that the assay is capable of detecting the rarer isoforms of p190 and p210, and the p230 variant (μbcr).
DETECTABLE ISOFORMS |
p210 b2a3 |
b2a2 |
b3a2 |
b3a3 |
p190 e1a2 |
e1a3 |
p230 e19a2 |
e19a3 |
Ultra Rapid
Identification of the translocation within 20 minutes, starting form extracted RNA
One step, closed format
The assay works directly on 500 ng RNA with no need for multistep procedures: decreased risk of contamination and errors
Highly Specific
No false positive results and absence of primer dimers
Tested on 521 BCR-ABL negative cell lines RNA extracted by both Qiagen Rneasy kit and modified TRIzol and on 225 NTC, the assay shows >99.8% specificity
Extraction Method | Total No. Replicates | Sample Type | % Analytical Specificity |
Qiagen RNeasyTM Kit | 252 | Cell lines | 99.6 |
Modified TRIzolTM | 269 | Cell lines | 100 |
N/A | 225 | Cell lines | 100 |
Highly Sensitive
One traslocated RNA in 1000 wild type is reproducible detected (>95% of cases).
K562 and TOM-1 10-4 dilutions were detected in ≥ 95% of replicates; K562 10-4 / TOM-1 10-4 dilutions extracted with Qiagen RNeasy Kit and modified TRIzolTM were detected 87.5%/90% and 88.4%/85% respectively.
EXTRACTION METHOD
QIAGEN RNEASY KIT | MODIFIED TRIZOL |
Limit of Detection | Limit of Detection |
K562 10-3 | K562 10-3 |
TOM-1 10-3 | TOM-1 10-3 |
Clinically Validated
One traslocated RNA in 1000 wild type is reproducible detected (>95% of cases)
Sample status | Number of diagnostic results | % Agreement with laboratory developed PCR method (BIOMED protocol) |
p190 Positive | 30 | 100% |
p210 Positive | 30 | 100% |
p190 or p210 Negative | 140 | 100% |
Robust
Superior robustness to inhibitors, RNA degradation and suboptimal target quantities.
The intrinsic robustness of the enzyme employed in Q-LAMP results in a enhanced robustness versus the classical inhibitor factors of PCR.
Superiority vs. PCR
Q-LAMP is a very rapid, easy, accurate, convenient and robust method for detection of BCR-ABL translocations.
Can be implemented even in not specialized laboratories for a timely Philadelphia Positive Leukemias diagnosis and as a screening for exclusion of Philadelphia Positive conditions.
Q-LAMP | RT-PCR (Biomed) | |
RNA input | 500 ng/rx robust down to 25 ng/rx | 1μg/rx |
Steps | 1 | 3 |
Assay format | MULTIPLEX | SIMPLEX |
Control of reaction | INTERNAL | EXTERNAL |
Robustness | – to chemical contamination – to PCR inhibitors – to degraded samples | To chemical contamination |
Result interpretation | OBJECTIVE | SUBJECTIVE |
Time to result | 60min | 3h 30min |
For use on
Ordering Info
PRODUCT | CODE | REACTIONS |
Iam BCR-ABL | V31BCR | 24 |
Please click below for more information
- Product: Iam BCR-ABL Kit
- SKU:
- Availability: In Stock
Tags: Iam BCR-ABL Kit